Patient Reported Outcomes Conference Key Takeaways
On Monday and Tuesday of this week, CBI's 9th Forum on Patient Reported Outcomes was held in Philadelphia. The expert presenters from pharma, CROs, service providers and academic health centers covered a variety of topics on how to ensure the validity of PRO concepts, patient data and new technologies.
The co-chairs of the event, Ari Gnanasakthy, Executive Director, HE&OR, Novartis, and Susan Vallow, Director for Patient Reported Outcomes at Janssen Global Services, LLC, noted the following emerging themes from the conference as important to the PRO audience in the upcoming months: FDA/EMA regulations; increasing use of PRO in the post-registration environment; how best to use PRO as a quality measure; mixed modality usage and how new collaborative initiatives across the industry are being used to combat inefficiencies in development and how they impact PROs.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
